Perrigo Company Plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company Plc, an Ireland-incorporated pharmaceutical company, filed this Current Report on Form 8-K on May 7, 2014. The filing announces the release of earnings results for the third quarter and year-to-date fiscal 2014.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.1), which is referenced but not included in the provided text.
Material Changes and Non-GAAP Adjustments
Management utilizes non-GAAP measures to evaluate core business performance by excluding specific one-time or non-core items. The filing details the following exclusions for the reported periods:
- Third Quarter Fiscal 2014: Amortization of acquired intangibles, transaction charges, contingent consideration write-ups, litigation settlements, restructuring charges, and losses on equity/investment sales.
- Year-to-Date Fiscal 2014: Includes the Q3 items plus write-offs of in-process research and development and escrow settlements.
- Third Quarter Fiscal 2013: Amortization of acquired intangibles, inventory step-up charges, acquisition charges, and losses on investment sales.
- Year-to-Date Fiscal 2013: Includes Q3 2013 items plus acquisition and severance charges.
Guidance, Outlook, and Management Commentary
Management uses adjusted earnings as a primary indicator for planning, forecasting, and measuring performance against budgets. The filing outlines items that will be excluded from Fiscal 2014 guidance, including amortization of acquired intangibles, transaction charges, litigation settlements, restructuring charges, write-offs of in-process research and development, losses on equity/investment sales, and escrow settlements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP financial figures (revenue, net income, EPS).
- Verify the reconciliation tables between non-GAAP measures and U.S. GAAP measures as required by Regulation G.
- Assess the magnitude of excluded items (e.g., restructuring charges, litigation settlements) to understand their impact on reported earnings.
- Confirm the specific details of the "loss on equity investments" and "loss on sales of investments" mentioned in the exclusions.